search icon
stok-img

Stoke Therapeutics Inc, Common Stock

STOK

NSQ

$9.73

+$0.3

(3.18%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$518.67M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
11.2262
Volume info-icon
This is the total number of shares traded during the most recent trading day.
453.27K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.20
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$5.35 L
$17.58 H
$9.73

About Stoke Therapeutics Inc, Common Stock

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSTOKSectorS&P500
1-Week Return2.42%0.71%0.79%
1-Month Return2.31%-5.6%6.04%
3-Month Return23.95%-11.72%-1.11%
6-Month Return-19.65%-10.81%-2.39%
1-Year Return-29.34%-7.12%11.69%
3-Year Return-19.65%-0.57%42.29%
5-Year Return-64.82%27.64%93.12%
10-Year Return-61.95%75.45%179.21%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-3.00M12.40M8.78M36.55M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":8.21,"profit":true},{"date":"2022-12-31","value":33.94,"profit":true},{"date":"2023-12-31","value":24.02,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue1.93M2.23M3.54M4.73M4.44M[{"date":"2020-12-31","value":40.73,"profit":true},{"date":"2021-12-31","value":47.16,"profit":true},{"date":"2022-12-31","value":74.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":93.93,"profit":true}]
Gross Profit(1.93M)(2.23M)12.40M8.78M32.11M[{"date":"2020-12-31","value":-6,"profit":false},{"date":"2021-12-31","value":-6.94,"profit":false},{"date":"2022-12-31","value":38.63,"profit":true},{"date":"2023-12-31","value":27.34,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(Infinity%)(74.33%)100.00%100.00%87.85%[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":-74.33,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":87.85,"profit":true}]
Operating Expenses53.04M86.06M116.76M123.55M137.93M[{"date":"2020-12-31","value":38.46,"profit":true},{"date":"2021-12-31","value":62.4,"profit":true},{"date":"2022-12-31","value":84.65,"profit":true},{"date":"2023-12-31","value":89.58,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(53.04M)(86.06M)(104.36M)(114.77M)(101.37M)[{"date":"2020-12-31","value":-5304400000,"profit":false},{"date":"2021-12-31","value":-8606500000,"profit":false},{"date":"2022-12-31","value":-10435600000,"profit":false},{"date":"2023-12-31","value":-11477300000,"profit":false},{"date":"2024-12-31","value":-10137200000,"profit":false}]
Total Non-Operating Income/Expense1.54M380.00K6.41M18.87M25.03M[{"date":"2020-12-31","value":6.17,"profit":true},{"date":"2021-12-31","value":1.52,"profit":true},{"date":"2022-12-31","value":25.61,"profit":true},{"date":"2023-12-31","value":75.41,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(52.24M)(85.81M)(101.07M)(104.70M)(88.98M)[{"date":"2020-12-31","value":-5224300000,"profit":false},{"date":"2021-12-31","value":-8580500000,"profit":false},{"date":"2022-12-31","value":-10106700000,"profit":false},{"date":"2023-12-31","value":-10469900000,"profit":false},{"date":"2024-12-31","value":-8898100000,"profit":false}]
Income Taxes(1.63M)(1.09M)(7.96M)4.56M(88.98M)[{"date":"2020-12-31","value":-35.78,"profit":false},{"date":"2021-12-31","value":-23.99,"profit":false},{"date":"2022-12-31","value":-174.45,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-1950.86,"profit":false}]
Income After Taxes(50.61M)(84.71M)(93.11M)(109.26M)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(52.24M)(85.81M)(101.07M)(103.40M)(88.98M)[{"date":"2020-12-31","value":-5224300000,"profit":false},{"date":"2021-12-31","value":-8580500000,"profit":false},{"date":"2022-12-31","value":-10106700000,"profit":false},{"date":"2023-12-31","value":-10339600000,"profit":false},{"date":"2024-12-31","value":-8898100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(50.61M)(84.71M)(93.11M)(104.70M)(88.98M)[{"date":"2020-12-31","value":-5061100000,"profit":false},{"date":"2021-12-31","value":-8471100000,"profit":false},{"date":"2022-12-31","value":-9311000000,"profit":false},{"date":"2023-12-31","value":-10469900000,"profit":false},{"date":"2024-12-31","value":-8898100000,"profit":false}]
EPS (Diluted)(1.56)(2.33)(2.60)(2.37)(1.68)[{"date":"2020-12-31","value":-156,"profit":false},{"date":"2021-12-31","value":-233,"profit":false},{"date":"2022-12-31","value":-260,"profit":false},{"date":"2023-12-31","value":-237,"profit":false},{"date":"2024-12-31","value":-167.91,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

STOK
Cash Ratio 8.00
Current Ratio 8.41

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

STOK
ROA (LTM) 7.81%
ROE (LTM) 20.50%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

STOK
Debt Ratio Lower is generally better. Negative is bad. 0.03
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

STOK
Trailing PE 11.45
Forward PE NM
P/S (TTM) 2.78
P/B 1.52
Price/FCF 4
EV/R 0.92
EV/Ebitda 4.37

FAQs

What is Stoke Therapeutics Inc share price today?

Stoke Therapeutics Inc (STOK) share price today is $9.73

Can Indians buy Stoke Therapeutics Inc shares?

Yes, Indians can buy shares of Stoke Therapeutics Inc (STOK) on Vested. To buy Stoke Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in STOK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Stoke Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Stoke Therapeutics Inc (STOK) via the Vested app. You can start investing in Stoke Therapeutics Inc (STOK) with a minimum investment of $1.

How to invest in Stoke Therapeutics Inc shares from India?

You can invest in shares of Stoke Therapeutics Inc (STOK) via Vested in three simple steps:

  • Click on Sign Up or Invest in STOK stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Stoke Therapeutics Inc shares
What is Stoke Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Stoke Therapeutics Inc (STOK) is $17.58. The 52-week low price of Stoke Therapeutics Inc (STOK) is $5.35.

What is Stoke Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Stoke Therapeutics Inc (STOK) is 11.2262

What is Stoke Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Stoke Therapeutics Inc (STOK) is 1.52

What is the Market Cap of Stoke Therapeutics Inc?

The market capitalization of Stoke Therapeutics Inc (STOK) is $518.67M

What is Stoke Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Stoke Therapeutics Inc is STOK

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top